Did you know?
ChinaBio® Group is an investment, consulting and media firm helping western life science companies achieve success in China. ChinaBio works with U.S., European and APAC companies seeking partnerships, acquisitions, novel technologies and funding in China.  

>> Learn more…

Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Boehringer Ingelheim Plans Shanghai Animal Vaccine R&D Center

publication date: Mar 13, 2012
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Boehringer Ingelheim will invest $15.7 million to build an Asian R&D center located in Shanghai’s Zhangjiang HiTech Park. The center, the first animal health center in China for BI, will be devoted to developing vaccines for diseases that are prevalent among China’s livestock. It will contain space for 70 workstations. BI positioned the investment as part of the company’s larger initiative to increase veterinary revenues in China. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.


Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Alibaba IPO
Event Updates
Greg Scott will be attending and speaking at this event:
 
 
Hope to see you there!
 
ChinaBio® Events
 
China Forum 2014

Frankfurt, Germany
November 2, 2014

>> More events...

Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Sponsors